# Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

> **NCT05471531** · PHASE4 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 3000 (actual)

## Conditions studied

- Influenza and Pneumonia

## Interventions

- **BIOLOGICAL:** Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
- **BIOLOGICAL:** Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine

## Key facts

- **NCT ID:** NCT05471531
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-13
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-07-10
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05471531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05471531, "Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05471531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*